#AS­CO24: No­var­tis' new CML treat­ment tops old­er drugs, in­clud­ing Gleevec, in Phase 3 tri­al

CHICA­GO — No­var­tis said its chron­ic myeloid leukemia drug Scem­blix was bet­ter than its own first-gen­er­a­tion block­buster med­i­cine and an in­ves­ti­ga­tor’s choice of sec­ond-gen­er­a­tion treat­ments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER